How have coronavirus (COVID-19) restrictions impacted people affected by Parkinson’s?
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Protecting the future of research after coronavirus (COVID-19)
Medical research charities have come together and are asking the government to act now and set up a fund to ensure that the future of charity-funded research is protected
Replacing cells lost in Parkinson’s
New one-step process converts cells inside the brain into dopamine-producing cells to replace those lost in Parkinson's.
Help researchers understand coronavirus
New opportunities to take part in research have been added to the Take Part Hub, including studies specifically looking to gather people's experiences of social isolation.
Researchers identify key player in genetic Parkinson’s
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
We've launched a funding programme for studies into non-drug treatments for Parkinson’s
Parkinson’s UK is launching a new funding programme to support innovative studies into non-drug treatments for Parkinson’s.
Survey shows a lack of awareness of brain donation for research
Our survey of 2,000 UK adults shows that research is at risk due to a lack of awareness surrounding brain donation.
Cannabis extract may hold key to stop pain in Parkinson's
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Potential treatment for dyskinesia in Parkinson’s
Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Initial results from CDNF clinical trial announced
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.